Clinical trials: Plasmodium Vivax Malaria, open to volunteers
Malaria Vivax
Clinical Trial to Evaluate the Safety and Immunogenicity of the Vivaxin Vaccine for Malaria Caused by Plasmodium Vivax."
Phase 1 clinical trial to evaluate the safety, reactogenicity, and immunogenicity of a malaria vaccine named Vivaxin against the protozoan Plamodium vivax in participants with no prior malaria infection
- Trial name
- Vivaxin-001 (NCT07172724)
- Testing
- Vivaxin vaccine manufactured by CT Vacinas/Cristália Laboratory
- Where
- Brazil
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Federal University of Minas Gerais
Plasmodium Vivax Infection
A Controlled Human Vivax Malaria Infection Study Through Inoculation of Infected Erythrocytes
The primary objectives of this study are to assess the safety and feasibility of blood-stage controlled human P. vivax malaria infection (CHMI) in healthy adult Thai volunteers through experimental injection of cryopreserved P.
- Trial name
- MIST2 (NCT05071079)
- Testing
- An inoculum of malaria parasitised red blood cells with whole dose blood-stage inoculum, An inoculum of malaria parasitised red blood cells with 1:5 dilution blood-stage inoculum, An inoculum of malaria parasitised red blood cells with 1:10 dilution blood-stage inoculum
- Where
- Thailand
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Plasmodium Vivax Malaria, Plasmodium Vivax Infection
Phase IIa/b Trial of PvCS/Montanide ISA-51 Malaria Vaccine in Adults in Chocó, Colombia
This clinical study will evaluate an investigational malaria vaccine called PvCS/Montanide ISA-51 to determine whether it is safe and whether it can protect adults from infection with Plasmodium vivax, one of the main parasites…
- Conditions
- Plasmodium Vivax Malaria, Plasmodium Vivax Infection, Malaria Prevention
- Trial name
- PvCS/M51 (NCT07373301)
- Testing
- PvCS/Montanide ISA-51 VG Vaccine
- Where
- Colombia
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Malaria Vaccine and Drug Development Center
Drug Pharmacokinetics in Healthy Volunteers
Postpartum 8-aminoquinoline Breast Milk Study
In Papua New Guinea, administration of primaquine (PQ) or tafenoquine (TQ) to breastfeeding mothers is contraindicated during the first six months postpartum, when infants are recommended to be exclusively breastfed, because of a…
- Trial name
- NCT07060404
- Testing
- Daily primaquine (0.5 mg/kg per day) for 14 days given with food food and water, Daily primaquine 1 mg/kg per day for 7 days given with food and water, Single-dose tafenoquine given with food and water to prevent gastrointestinal discomfort
- Where
- Papua New Guinea
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Curtin University
Pharmacokinetics of Tafenoquine
Investigating the Pharmacokinetics of Tafenoquine in Healthy Papua New Guinean Children
Plasmodium vivax is the most geographically widespread malaria species and the second largest contributor to symptomatic malaria worldwide.
- Trial name
- NCT07052162
- Testing
- Single dose tafenoquine (10 mg/kg) given with water, Single dose tafenoquine (10 mg/kg) given with fat
- Where
- Papua New Guinea
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Curtin University
Malaria
Three-arm Cluster Randomised Control Trial Evaluation of Guardian Spatial Emanator as a Complimentary Vector Control Tool in Papua New Guinea
Malaria cases are increasing in Papua New Guinea, partly because insecticide-treated nets do not fully protect people, especially from mosquitoes that bite outdoors.
- Trial name
- WinMal (NCT07912528)
- Testing
- Spatial emanator outdoor, Spatial emanator indoor
- Where
- Papua New Guinea
- Volunteers
- 4,350 people, healthy volunteers welcome
- Sponsor
- Macfarlane Burnet Institute for Medical Research and Public Health Ltd
Plasmodium Vivax Malaria, Malaria
FocaL Mass Drug Administration for Vivax Malaria Elimination
FLAME is an open-label cluster-randomized controlled trial that aims to determine the effectiveness of focal mass drug administration (fMDA) to reduce the incidence of Plasmodium vivax malaria in the Loreto Department in Peru.
- Trial name
- FLAME (NCT05690841)
- Testing
- Focal Mass Drug Administration (fMDA)
- Where
- Peru
- Volunteers
- 7,530 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Malaria
Induced Blood-Stage Malaria in Healthy Malaria-Naive Adults to Assess the Safety and Infectivity of Plasmodium Vivax Challenge Agent and Evaluate Transmission in Mosquito Feeding Assays
Background: Malaria is a disease caused by parasites transmitted to people by mosquitoes. Around the world, there were 241 million cases and 627,000 deaths from malaria in 2020.
- Trial name
- NCT06607003
- Testing
- P. vivax challenge agent derived from PvHMB-CCE001
- Where
- United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Plasmodium Vivax Infection
Clinical Study to Assess Minimum Mosquito Bites for P. Vivax Infection in Thai Adults
This study is a human challenge study to assess the minimum infective mosquito bite dose in a controlled human malaria Infection (via P. vivax sporozites) in healthy volunteers. The results will inform the development of a P.
- Trial name
- MIST4 (NCT07257965)
- Testing
- Mosquito bite (1 or 2 or 3)
- Where
- Thailand
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Plasmodium Vivax Infection, Malaria Vaccine
A Safety, Immunogenicity and Efficacy Study of PvRII/Matrix-M in Healthy Thai Adults Living in Thailand ( MIST3 )
This project is the third part of a 5-year research program entitled "Malaria Infection Studies in Thailand (MIST)" and known as MIST3.
- Trial name
- MIST3 (NCT05380388)
- Testing
- Malaria Vaccine, HBV vaccine
- Where
- Thailand
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Malaria Vaccine
Safety and Immunogenicity of the Recombinant Malaria Vaccines in Healthy Adults Aged 18-50 Years
This is a clinical trial in which healthy volunteers will receive one of three investigational malaria vaccines (LYB014, LYB017, and LYB027) administered in combination with the A02B adjuvant, or the A02B adjuvant alone as the…
- Trial name
- NCT07831226
- Testing
- LYB014 low dose, LYB014 high dose, LYB017 low dose
- Where
- Australia
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Guangzhou Patronus Biotech Co., Ltd.